Cardiac involvement in peripheral neuropathies

Journal of Clinical Neuromuscular Disease

Volumn 17, Issue 3, 2016, Pages 120-128

  Burakgazi, Ahmet Z ^a,b   Almahameed, Soufian ^b,c  

^a CARILION CLINIC   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c Department of Medicine   (United States)

Author keywords

Cardiac involvement; Peripheral neuropathy

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ATRIAL NATRIURETIC FACTOR; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C PEPTIDE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; ESMOLOL; FLUDROCORTISONE ACETATE; GANGLIOSIDE; LABETALOL; MIDODRINE; MINOCYCLINE; NITROPRUSSIDE SODIUM; NORADRENALIN; OCTREOTIDE; PARAPROTEIN; PREALBUMIN; PYRIDOSTIGMINE; RENIN; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; VANILMANDELIC ACID;

ACUTE CORONARY SYNDROME; AMYLOID NEUROPATHY; AMYLOIDOSIS; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BRADYCARDIA; CARDIAC AUTONOMIC NEUROPATHY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIAGNOSTIC TEST; EXERCISE TOLERANCE; GENE PRODUCT; GUILLAIN BARRE SYNDROME; HEART ARREST; HEART ARRHYTHMIA; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RATE; HEART SINOATRIAL BLOCK; HEART VENTRICLE ARRHYTHMIA; HEREDITARY MOTOR SENSORY NEUROPATHY; HIV ASSOCIATED NEUROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; MYOCARDITIS; NEUROPATHY; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; QT PROLONGATION; REVIEW; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SMALL FIBER NEUROPATHY; SUPRAVENTRICULAR TACHYCARDIA; VASCULAR RESISTANCE; COMPLICATION; HEART DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES;

HEART DISEASES; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84959925491     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0000000000000106     Document Type: Review

References (69)

1. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010;33:434-441.
2. Ziegler D, Gries FA, Spuler M, et al. The epidemiology of diabetic neuropathy. Diabetic cardiovascular autonomic neuropathy multicenter study group. J Diabetes Complications. 1992;6:49-57.
3. Maser RE, Lenhard MJ. Effect of treatment with losartan on cardiovascular autonomic and large sensory nerve fiber function in individuals with diabetes mellitus: a 1-year randomized, controlled trial. J Diabetes Complications. 2003;17:286-291.
4. Abd El Dayem SM, Battah AA, Soliman RA. Natural progression of cardiac autonomic neuropathy in patients with type 1 diabetes: a four-year follow-up study. Anadolu Kardiyol Derg. 2011;11:224-231.
5. Laitinen T, Lindstrom J, Eriksson J, et al. Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance. Diabet Med. 2011;28:699-704.
6. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011.
7. Voulgari C, Psallas M, Kokkinos A, et al. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. 2011;25:159-167.
8. Motataianu A, Balasa R, Voidazan S, et al. Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus. Biomed Res Int. 2013;2013:507216.
9. Ciccacci C, Di Fusco D, Cacciotti L, et al. TCF7L2 gene polymorphisms and type 2 diabetes: association with diabetic retinopathy and cardiovascular autonomic neuropathy. Acta Diabetol. 2013;50:789-799.
10. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553-1579.
11. Compostella C, Compostella L, D'Elia R. The symptoms of autonomic dysfunction in HIV-positive Africans. Clin Auton Res. 2008;18:6-12.
12. Compostella C, Compostella L, D'Elia R. Cardiovascular autonomic neuropathy in HIV-positive African patients. Minerva Cardioangiol. 2008;56:417-428.
13. Ruttimann S, Hilti P, Spinas GA, et al. High frequency of human immunodeficiency virus-associated autonomic neuropathy and more severe involvement in advanced stages of human immunodeficiency virus disease. Arch Intern Med. 1991;151:2441-2443.
14. Stella P, Ellis D, Maser RE, et al. Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. J Diabetes Complications. 2000;14:1-6.
15. Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48:164-171.
16. Palazzo P, Maggio P II, Altavilla R, et al. Cerebral hemodynamics and systemic endothelial function are already impaired in well-controlled type 2 diabetic patients, with short-term disease. PLoS One. 2013;8:e83287.
17. Vinik AI, Erbas T. Cardiovascular autonomic neuropathy: diagnosis and management. Curr Diab Rep. 2006;6:424-430.
18. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med. 2001;68:928-930, 932, 934-44.
19. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care. 2001;24:339-343.
20. Bagherzadeh A, Nejati-Afkham A, Tajallizade-Khoob Y, et al. Association of cardiac autonomic neuropathy with arterial stiffness in type 2 diabetes mellitus patients. J Diabetes Metab Disord. 2013;12:55.
21. Moura-Tonello SC, Takahashi AC, Francisco CO, et al. Influence of type 2 diabetes on symbolic analysis and complexity of heart rate variability in men. Diabetol Metab Syndr. 2014;6:13.
22. Canani LH, Copstein E, Pecis M, et al. Cardiovascular autonomic neuropathy in type 2 diabetes mellitus patients with peripheral artery disease. Diabetol Metab Syndr. 2013;5:54.
23. Statsenko ME, Turkina SV, Shalaeva SS, et al. Impaired cardiac structural and functional parameters in patients with chronic heart failure and diabetic cardiac autonomic neuropathy [in Russian]. Ter Arkh. 2013;85:23-28.
24. Gonin JM, Kadrofske MM, Schmaltz S, et al. Corrected Q-T interval prolongation as diagnostic tool for assessment of cardiac autonomic neuropathy in diabetes mellitus. Diabetes Care. 1990;13:68-71.
25. Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res. 1995;5:48-52.
26. Sawicki PT, Kiwitt S, Bender R, et al. The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus. J Intern Med. 1998;243:49-56.
27. Jung CH, Baek AR, Kim KJ, et al. Association between cardiac autonomic neuropathy, diabetic retinopathy and carotid atherosclerosis in patients with type 2 diabetes. Endocrinol Metab (Seoul). 2013;28:309-319.
28. Dinh W, Futh R, Lankisch M, et al. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet Med. 2011;28:311-318.
29. Wu JS, Yang YC, Lin TS, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007;92:3885-3889.
30. Rolim LC, de Souza JS, Dib SA. Tests for early diagnosis of cardiovascular autonomic neuropathy: critical analysis and relevance. Front Endocrinol (Lausanne). 2013;4:173.
31. Orchard TJ, CE LL, Maser RE, Kuller LH. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract. 1996;34(suppl):S165-S171.
32. Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care. 1997;20:355-361.
33. Ebbehoj E, Poulsen PL, Hansen KW, et al. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia. 2002;45:965-975.
34. Manzella D, Barbieri M, Rizzo MR, et al. Role of free fatty acids on cardiac autonomic nervous system in noninsulin-dependent diabetic patients: effects of metabolic control. J Clin Endocrinol Metab. 2001;86:2769-2774.
35. Syngle A, Verma I, Krishan P, et al. Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2014;35:1067-1073.
36. Balcioglu AS, Muderrisoglu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015;6:80-91.
37. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5:17-39.
38. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358:615-624.
39. Freeman R. Autonomic peripheral neuropathy. Lancet. 2005;365:1259-1270.
40. Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13:930-936.
41. Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. Diabetologia. 1997;40:476-481.
42. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre syndrome: an update. J Clin Neurosci. 2009;16:733-741.
43. Walling AD, Dickson G. Guillain-Barre syndrome. Am Fam Physician. 2013;87:191-197.
44. Burakgazi AZ, Hoke A. Respiratory muscle weakness in peripheral neuropathies. J Peripher Nerv Syst. 2010;15:307-313.
45. Asahina M, Kuwabara S, Suzuki A, et al. Autonomic function in demyelinating and axonal subtypes of Guillain-Barre syndrome. Acta Neurol Scand. 2002;105:44-50.
46. Pfeiffer G, Schiller B, Kruse J, et al. Indicators of dysautonomia in severe Guillain-Barre syndrome. J Neurol. 1999;246:1015-1022.
47. Mukerji S, Aloka F, Farooq MU, et al. Cardiovascular complications of the Guillain-Barre syndrome. Am J Cardiol. 2009;104:1452-1455.
48. Flachenecker P. Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis. J Neurol. 2007;254(suppl 2):II96-II101.
49. Winer JB, Hughes RA. Identification of patients at risk of arrhythmia in the Guillain-Barre syndrome. Q J Med. 1988;68:735-739.
50. Greenland P, Griggs RC. Arrhythmic complications in the Guillain-Barre syndrome. Arch Intern Med. 1980;140:1053-1055.
51. Kordouni M, Jibrini M, Siddiqui MA. Long-term transvenous temporary pacing with active fixation bipolar lead in the management of severe autonomic dysfunction in Miller-Fisher syndrome: a case report. Int J Cardiol. 2007;117:e10-e12.
52. Annane D, Baudrie V, Blanc AS, et al. Short-term variability of blood pressure and heart rate in Guillain-Barre syndrome without respiratory failure. Clin Sci (Lond). 1999;96:613-621.
53. Tuck RR, McLeod JG. Autonomic dysfunction in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1981;44:983-990.
54. Zochodne DW. Autonomic involvement in Guillain-Barre syndrome: a review. Muscle Nerve. 1994;17:1145-1155.
55. Bernstein R, Mayer SA, Magnano A. Neurogenic stunned myocardium in Guillain-Barre syndrome. Neurology. 2000;54:759-762.
56. Finkelstein JS, Melek BH. Guillain-Barre syndrome as a cause of reversible cardiomyopathy. Tex Heart Inst J. 2006;33:57-59.
57. Dagres N, Haude M, Baumgart D, et al. Assessment of coronary morphology and flow in a patient with Guillain-Barre syndrome and ST-segment elevation. Clin Cardiol. 2001;24:260-263.
58. Gabbai AA, Castelo A, Oliveira AS. HIV peripheral neuropathy. Handb Clin Neurol. 2013;115:515-529.
59. Freeman R, Roberts MS, Friedman LS, et al. Autonomic function and human immunodeficiency virus infection. Neurology. 1990;40:575-580.
60. Gluck T, Degenhardt E, Scholmerich J, et al. Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication. Clin Auton Res. 2000;10:17-22.
61. Figueroa JJ, Dyck PJ, Laughlin RS, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2012;78:702-708.
62. Lyu RK, Tang LM, Wu YR, et al. Cardiovascular autonomic function and sympathetic skin response in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002;26:669-672.
63. Yamamoto K, Watarai M, Hashimoto T, et al. Chronic inflammatory demyelinating polyradiculoneuropathy with autonomic involvement. Muscle Nerve. 2005;31:108-112.
64. Burakgazi AZ, Alsowaity B, Burakgazi ZA, et al. Bladder dysfunction in peripheral neuropathies. Muscle Nerve. 2012;45:2-8.
65. Auer-Grumbach M, De Jonghe P, Verhoeven K, et al. Autosomal dominant inherited neuropathies with prominent sensory loss and mutilations: a review. Arch Neurol. 2003;60:329-334.
66. Isner JM, Hawley RJ, Weintraub AM, et al. Cardiac findings in Charcot-Marie-Tooth disease. A prospective study of 68 patients. Arch Intern Med. 1979;139:1161-1165.
67. Sevillano Fernandez JA, Paz Fraile A, Cano Ballesteros JC, Villalba Garcia MV, Otero Perez R, Gilsanz Fernandez C. [Charcot-Marie-Tooth disease, dilated myocardiopathy and cardiac conduction disorders]. An Med Interna. 1994;11:455-456.
68. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
69. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166:1805-1813.